Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Prostatic Neoplasms, Castration-Resistant × xentuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

enzalutamide 6 radium Ra 223 dichloride 4 Abiraterone Acetate 2 zimberelimab 1 xentuzumab 1 sacituzumab govitecan 1 quemliclustat 1 pembrolizumab 1 atezolizumab 1 apalutamide 1 Standard of Care 1 Radium-223 1 Nivolumab 1 Ipilimumab 1 Drug Therapy 1 Docetaxel 1 CTLA-4 Antigen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02204072 2025-07-15

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Boehringer Ingelheim

Phase 1 Completed

120 enrolled 28 charts

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡